Loading
Vaccine Efficacy / Rotavirus Vaccines / Rotavirus Infections · Journal article
Human Vaccines & Immunotherapeutics · June 4, 2026
A consensus or society position rather than new primary data.
This narrative review examines immunological factors underlying the substantial gap in rotavirus vaccine efficacy between high-income countries (85–90%) and low- and middle-income countries (45–65%), and outlines research priorities for developing next-generation vaccines. It is an expert synthesis of mechanisms and challenges, not a primary evidence base, and should inform vaccine development strategy rather than direct clinical practice.
Narrative review article. Children under 5 years of age worldwide; focus on low- and middle-income countries versus high-income countries..
Oral rotavirus vaccine efficacy is 85–90% in high-income countries but only approximately 45–65% in low- and middle-income countries Rotavirus causes an estimated 120,000 to 200,000 deaths annually among children under 5 years of age in LMICs IgA correlates with protection after natural infection and oral vaccination in the first year of life in low child mortality settings but does not capture clinical endpoints or predict individual protection
IgA correlates with protection after natural infection and oral vaccination in the first year of life in low child mortality settings but does not capture clinical endpoints or predict individual protection
Clinicians should understand that rotavirus vaccine efficacy is substantially lower in resource-limited settings and that current correlates of protection (IgA, neutralizing antibodies) may not fully predict individual clinical outcomes. This review identifies gaps in understanding that should inform vaccine development but does not provide new clinical recommendations beyond existing WHO guidance.
A narrative review synthesizing current knowledge on rotavirus vaccine immunology in LMICs and HICs, identifying research priorities but not presenting primary experimental or clinical trial data to support practice changes.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should understand that rotavirus vaccine efficacy is substantially lower in resource-limited settings and that current correlates of protection (IgA, neutralizing antibodies) may not fully predict individual clinical outcomes. This review identifies gaps in understanding that should inform vaccine development but does not provide new clinical recommendations beyond existing WHO guidance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Rotavirus is a highly contagious pathogen and a leading cause of severe diarrhea cases in children under 5 y of age worldwide. Although effective oral rotavirus vaccines have been developed and implemented globally, their performance varies substantially by setting. In high-income countries (HICs), these oral vaccines exhibit 85-90% efficacy in preventing rotavirus-associated hospitalizations, with protection lasting until at least 2 y of age. In contrast, vaccine efficacy in low- and middle-income countries (LMICs) is considerably lower, ranging from approximately 45% to 65%. To address this disparity, efforts are underway to develop next-generation rotavirus vaccines. In this review, we critically examine the immune responses elicited by natural rotavirus infection and by oral vaccination in both HICs and LMICs. The goal is to identify immunological factors associated with durable protection and to define key characteristics that an improved rotavirus vaccine should possess to achieve sustained high efficacy in LMICs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.